Navigation Links
Piggy-backing proteins ride white blood cells to wipe out metastasizing cancer
Date:1/6/2014

ITHACA, N.Y. Cornell biomedical engineers have discovered a new way to destroy metastasizing cancer cells traveling through the bloodstream lethal invaders that are linked to almost all cancer deaths by hitching cancer-killing proteins along for a ride on life-saving white blood cells.

"These circulating cancer cells are doomed," said Michael King, Cornell professor of biomedical engineering and the study's senior author. "About 90 percent of cancer deaths are related to metastases, but now we've found a way to dispatch an army of killer white blood cells that cause apoptosis the cancer cell's own death obliterating them from the bloodstream. When surrounded by these guys, it becomes nearly impossible for the cancer cell to escape."

Metastasis is the spread of a cancer cells to other parts of the body. Surgery and radiation are effective at treating primary tumors, but difficulty in detecting metastatic cancer cells has made treatment of the spreading cancers problematic, say the scientists.

King and his colleagues injected human blood samples, and later mice, with two proteins: E-selectin (an adhesive) and TRAIL (Tumor Necrosis Factor Related Apoptosis-Inducing Ligand). The TRAIL protein joined with the E-selectin protein was able to stick to leukocytes white blood cells abundant in the bloodstream. When a cancer cell comes into contact with TRAIL, which is nearly unavoidable in the frenzied flow of blood, the cancer cell essentially kills itself.

"The mechanism is surprising and unexpected in that this repurposing of white blood cells in flowing blood is more effective than directly targeting the cancer cells with liposomes or soluble protein," say the authors.

In the laboratory, King and his colleagues tested this concept's efficacy.

When treating cancer cells with the proteins in saline, they found a 60 percent success rate in killing the cancer cells. In normal laboratory conditions, the saline lacks white blood cells to serve as a carrier for the adhesive and killer proteins. Once the proteins were added to flowing blood that mimicked human-body conditions, however, the success rate in killing the cancer cells jumped to nearly 100 percent.

The study, "TRAIL-Coated Leukocytes that Kill Cancer Cells in the Circulation," was published online today in the journal Proceedings of the National Academy of Sciences.


'/>"/>

Contact: Melissa Osgood
mmo59@cornell.edu
607-255-2059
Cornell University
Source:Eurekalert

Related biology technology :

1. The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry
2. Multipotent Stem Cell Proteins Support Soft Tissue Regeneration
3. Multipotent Stem Cell Proteins Support Rejuvenation While Inhibiting Skin Cancer
4. Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Industry Trend: Worldwide Industry Latest Market Share, Investment Trends, Growth, Size, Strategy
5. Chemists develop innovative nano-sensors for multiple proteins
6. Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
7. Tenfold boost in ability to pinpoint proteins in cancer cells
8. Waters Unveils Industrys First Integrated LC/MS Platform for Proteins, Peptides, and Glycans Analysis at WCBP 2013
9. Intrinsically disordered proteins: A conversation with Rohit Pappu
10. Frost & Sullivan Recognizes MicroProtein Technologies for its Path-Breaking Production Technology for Recombinant Proteins in Bacteria
11. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):